Upstream Bio, Inc. (UPB)
1.59
-0.41
(-20.50%)
USD |
NASDAQ |
Nov 20, 16:00
1.62
+0.03
(+1.89%)
After-Hours: 20:00
Upstream Bio EPS Diluted (Quarterly) : -0.7519 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -0.7519 |
| June 30, 2026 | -0.7276 |
| March 31, 2026 | -0.7471 |
| December 31, 2025 | -0.7857 |
| September 30, 2025 | -0.6258 |
| Date | Value |
|---|---|
| June 30, 2025 | -0.7433 |
| March 31, 2025 | -0.5084 |
| December 31, 2024 | -0.4065 |
| September 30, 2024 | -0.3924 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | -0.0232 |
| Savara, Inc. | -0.1691 |
| Arrowhead Pharmaceuticals, Inc. | -3.029 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -41.19M |
| Revenue (Quarterly) | 0.395M |
| Total Expenses (Quarterly) | 41.59M |
| Enterprise Value | -119.43M |
| Gross Profit Margin (Quarterly) | 87.59% |
| Profit Margin (Quarterly) | -10.43K% |
| Earnings Yield | -189.5% |
| Normalized Earnings Yield | -189.27 |